Raski M, Sutherland C, Brar R From methadone to Methadose: lessons learned from methadone formulation change in British Columbia Can Fam Physician PubMed

Brar R, Grant C, DeBeck K, Milloy MJ, Fairbairn N, Wood E, Kerr T, Hayashi K Changes in drug use behaviors coinciding with the emergence of illicit fentanyl among people who use drugs in Vancouver, Canada Am J Drug Alcohol Abuse PubMed

Ickowicz S, Brar R, Nolan S Case study: naltrexone for the treatment of nitrous oxide use J Addict Med PubMed

Ickowicz S, Grant C, Nosova E, Boyd J, Brar R, Milloy MJ, Hayashi K, Nolan S Factors associated with the use of supervised consumption facilities among women who inject drugs in a Canadian setting J Addict Med PubMed

Giang V, Brar R, Sutherland C, Nolan S HIV treatment initiation and retention among individuals initiated on injectable opioid agonist therapy for severe opioid use disorder: a case series J Addict Med PubMed

Bach P, Robinson S, Sutherland C, Brar R Innovative strategies to support physical distancing among individuals with active addiction Lancet Psychiatry PubMed

Brar R, Fairbairn N, Colizza K, Ryan A, Nolan S Hospital initiated injectable opioid agonist therapy for the treatment of severe opioid use disorder: a case series J Addict Med PubMed

Brar R, Fairbairn N, Sutherland C, Nolan S Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine/naloxone micro-dosing - a case series Drug Alcohol Rev PubMed

Socías ME, Wood E, Dong H, Brar R, Bach P, Murphy SM, Fairbairn N Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial Contemp Clin Trials PubMed

Caulfield MDG, Brar R, Sutherland C, Nolan S Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach BMJ Case Rep PubMed